Early Discontinuation and Restart of Insulin in the Treatment of Type 2 Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Although the largest improvement in glycemic control occurs within the first 90 days of insulin therapy, little is known about early persistence on insulin therapy. This research aimed to identify predictors of early discontinuation and of subsequent restart of basal or mixture insulin among patients with type 2 diabetes mellitus (T2DM) and to assess the economic cost associated with such behaviors over a 1-year period. METHODS: Truven's Health Analytics Commercial Claims and Encounters database was utilized for the study. Logistic regressions were used to examine factors associated with early discontinuation of insulin (basal or mixture) and, among patients who discontinued early, the factors associated with restarting. Cost regressions were estimated using generalized linear models with a gamma distribution and logistic link. Kaplan-Meier survival curves were used to examine time to discontinuation and time to restart among those who discontinued. RESULTS: Multivariate analyses revealed that patient characteristics, prior healthcare resource utilization, comorbid diagnoses, and type of initiated insulin were associated with early discontinuation of insulin and of restarting among patients who discontinued early. Acute care (hospitalization and emergency room) costs were 9.6% higher among patients who discontinued early (P < 0.001), although outpatient, drug, and total costs were significantly lower among individuals who discontinued early. Among the early discontinuation subgroup, restarting insulin was associated with higher costs. Specifically: 11.3% higher acute care costs (P < 0.001), 24.0% higher outpatient costs (P < 0.001), 80.2% higher drug costs (P < 0.001), and 30.3% higher total costs (P < 0.001), compared to patients who discontinued early but did not restart insulin therapy in the 1-year post-period. CONCLUSION: Among patients with T2DM who were initiated on insulin therapy, early discontinuation of insulin and its subsequent restart were associated with significantly higher acute care costs, which may signal a more complex and challenging subgroup of patients who tend to be less engaged in outpatient care and may have poorer long-term outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s067 · Cited by 2,245
Boyle, J. P., Thompson, T. J., Gregg, E. W., Barker, L. E., & Williamson, D. F. (2010) · Population Health Metrics · doi:10.1186/1478-7954-8-29 · Cited by 1,309 · cited 1×
“The prevalence of diabetes is growing steeply, with some projections indicating that one in three Americans may have the disease by the year 2050 if recent incidence trends continue [2].”
BackgroundA systematic review of adherence with medications for diabetes
Cramer, J. A. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1218 · Cited by 1,203
Ho, P. M., Rumsfeld, J. S., Masoudi, F. A., McClure, D. L., Plomondon, M. E., Steiner, J. F., & Magid, D. J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.17.1836 · Cited by 1,135
Depression and Diabetes Treatment Nonadherence: A Meta-Analysis
Gonzalez, J. S., Peyrot, M., McCarl, L. A., Collins, E. M., Serpa, L., Mimiaga, M. J., & Safren, S. A. (2008) · Diabetes Care · doi:10.2337/dc08-1341 · Cited by 1,060 · cited 12×
“Conclusion: Among patients with T2DM who were initiated on insulin therapy, early discontinuation of insulin and its subsequent restart were associated with significantly higher acute care costs, which may signal a more complex and challenging subgroup of patients who tend to be less engaged in outpatient care and may…”
ResultInfluentialBalkrishnan, R., Rajagopalan, R., Camacho, F. T., Huston, S. A., Murray, F. T., & Anderson, R. T. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80347-8 · Cited by 350 · cited 1×
“A large body of literature on T2DM has likewise shown a link between poor adherence and worse outcomes, including an increased risk of hospitalization [24–29].”
BackgroundHalpern, R., Iqbal, S. U., Kazis, L. E., Macarios, D., & Badamgarav, E. (2011) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2011.17.1.25 · Cited by 94
Cited by
Guerci, B., Chanan, N., Kaur, S., Jasso-Mosqueda, J. G., & Lew, E. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0590-x · Cited by 106
A Systematic Review of Insulin Adherence Measures in Patients with Diabetes
Stolpe, S., Kroes, M. A., Webb, N., & Wisniewski, T. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.11.1224 · Cited by 77
Insights into optimal basal insulin titration in type 2 diabetes: Results of a quantitative survey
Berard, L., Bonnemaire, M., Mical, M., & Edelman, S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13064 · Cited by 69
Steenkamp, D., Eby, E. L., Gulati, N., & Liao, B. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/1932296821997923 · Cited by 33
Garnero, T. L., Davis, N. J., Perez-Nieves, M., Hadjiyianni, I., Cao, D., Ivanova, J. I., & Peyrot, M. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1457396 · Cited by 14
“higher likelihood of persistence [14,15], while others found no significant association between gender and persistence [20,21].”
BackgroundSelf-citation
Metadata
- Authors
- Ascher-Svanum, H., Lage, M. J., Perez-Nieves, M., Reaney, M. D., Lorraine, J., Rodriguez, A., & Treglia, M.
- Venue
- Diabetes Therapy
- Published
- 2014-04-30
- Volume
- 5
- Issue
- 1
- Pages
- 225-242
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- OpenAlex
- W2041650397
- Cited by
- 50
- References
- 9
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early Discontinuation and Restart of Insulin in the Treatment of Type 2 Diabetes Mellitus. https://app.cochat.ai/papers/10.1007/s13300-014-0065-z
- The paper
- Ascher-Svanum, H., Lage, M. J., Perez-Nieves, M., Reaney, M. D., Lorraine, J., Rodriguez, A., & Treglia, M. (2014). Early Discontinuation and Restart of Insulin in the Treatment of Type 2 Diabetes Mellitus. Diabetes Therapy. https://doi.org/10.1007/s13300-014-0065-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.